It envisions an ongoing review and planning process to ensure that the US always has access to critical supplies. This complements planning exercises that the DoD already does, and that all of government should be doing (but basically hasn't) through the DPAS process.
While some experts have called for *either* stockpiling resources *or* reshoring - the plan envisions an all of the above approach.
It notes that domestic manufacturing incentives and Buy America requires an update of trade agreement rules, many of which currently tilt against those objectives.
The plan notes the strong interdependence between tax avoidance and pharmaceutical offshoring, e.g. Big Pharma's love affair with tax haven Ireland.

Without naming Ireland, this constitutes a warning of big changes to come.
Most other countries have their public health care providers negotiate bulk pharmaceuticals with an eye towards keeping down medicine and device costs.

The US doesn't: Biden pledges to reverse that.
The Trump administration has not used many of the considerable powers of the Defense Production Act (DPA) to solve supply chain problems. Biden pledges to.
You can follow @toddntucker.
Tip: mention @twtextapp on a Twitter thread with the keyword “unroll” to get a link to it.

Latest Threads Unrolled: